These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1703780)

  • 21. Clinical assessment of dopamine receptor blockade.
    Sedvall G; Bjerkenstedt L; Lindström L; Wode-Helgodt B
    Life Sci; 1978 Aug; 23(5):425-9. PubMed ID: 29184
    [No Abstract]   [Full Text] [Related]  

  • 22. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid amine metabolites in acute schizophrenia.
    Post RM; Fink E; Carpenter WT; Goodwin FK
    Arch Gen Psychiatry; 1975 Aug; 32(8):1063-9. PubMed ID: 1156113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology.
    Peters JG
    Eur Neurol; 1979; 18(1):15-8. PubMed ID: 436860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF creatinine in schizophrenia.
    Swahn CG; Sedvall G
    Biol Psychiatry; 1988 Mar; 23(6):586-94. PubMed ID: 2451543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical appraisal of CSF monoamine metabolite studies in schizophrenia.
    Widerlöv E
    Ann N Y Acad Sci; 1988; 537():309-23. PubMed ID: 2462396
    [No Abstract]   [Full Text] [Related]  

  • 29. Amphetamine psychosis: behavioral and biochemical aspects.
    Angrist B; Sathananthan G; Wilk S; Gershon S
    J Psychiatr Res; 1974; 11():13-23. PubMed ID: 4461784
    [No Abstract]   [Full Text] [Related]  

  • 30. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia.
    Jacobsen LK; Frazier JA; Malhotra AK; Karoum F; McKenna K; Gordon CT; Hamburger SD; Lenane MC; Pickar D; Potter WZ; Rapoport JL
    Am J Psychiatry; 1997 Jan; 154(1):69-74. PubMed ID: 8988961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
    Rüther E; Schilkrut R; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):33-6. PubMed ID: 981320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gamma-hydroxybutyrate in the treatment of schizophrenia.
    Levy MI; Davis BM; Mohs RC; Trigos GC; Mathé AA; Davis KL
    Psychiatry Res; 1983 May; 9(1):1-8. PubMed ID: 6193548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
    Csernansky JG; Faull KF; Pfefferbaum A
    Psychiatry Res; 1988 Sep; 25(3):361-3. PubMed ID: 2460883
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopaminergic dsyfunction in Tourette syndrome.
    Singer HS; Butler IJ; Tune LE; Seifert WE; Coyle JT
    Ann Neurol; 1982 Oct; 12(4):361-6. PubMed ID: 6184010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication.
    Risch SC; Lewine RR
    Arch Gen Psychiatry; 1993 Aug; 50(8):670. PubMed ID: 7688212
    [No Abstract]   [Full Text] [Related]  

  • 38. Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
    Jibson M; Faull KF; Csernansky JG
    Biol Psychiatry; 1990 Oct; 28(7):595-602. PubMed ID: 1699614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of mianserin on negative symptoms in schizophrenia.
    Mizuki Y; Kajimura N; Imai T; Suetsugi M; Kai S; Kaneyuki H; Yamada M
    Int Clin Psychopharmacol; 1990 Apr; 5(2):83-95. PubMed ID: 1696292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biochemical mechanisms of extrapyramidal-motoric effect of haloperidol in man].
    Eben E; Ackenheil M; Raese J; Rüther E
    Arzneimittelforschung; 1974 Aug; 24(8):1133-5. PubMed ID: 4479374
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.